A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2

BACKGROUND: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the ability to measure antibody-based protection...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulford, Thomas S., Van, Huy, Gherardin, Nicholas A., Zheng, Shuning, Ciula, Marcin, Drummer, Heidi E., Redmond, Samuel, Tan, Hyon-Xhi, Boo, Irene, Center, Rob J., Li, Fan, Grimley, Samantha L., Wines, Bruce D., Nguyen, Thi H.O., Mordant, Francesca L., Ellenberg, Paula, Rowntree, Louise C., Kedzierski, Lukasz, Cheng, Allen C., Doolan, Denise L., Matthews, Gail, Bond, Katherine, Hogarth, P. Mark, McQuilten, Zoe, Subbarao, Kanta, Kedzierska, Katherine, Juno, Jennifer A., Wheatley, Adam K., Kent, Stephen J., Williamson, Deborah A., Purcell, Damian F.J., Anderson, David A., Godfrey, Dale I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641961/
https://www.ncbi.nlm.nih.gov/pubmed/34871960
http://dx.doi.org/10.1016/j.ebiom.2021.103729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641961/
https://www.ncbi.nlm.nih.gov/pubmed/34871960
http://dx.doi.org/10.1016/j.ebiom.2021.103729

Ejemplares similares